利拉鲁肽对新诊断2型糖尿病患者血清microRNA表达谱的影响

发布时间：2017-12-27 15:12

本文关键词：利拉鲁肽对新诊断2型糖尿病患者血清microRNA表达谱的影响　出处：《中国糖尿病杂志》2016年12期 　论文类型：期刊论文

【摘要】：目的探讨新诊断T2DM患者与健康人群血清microRNA(miRNA)表达谱的差异表达。分析利拉鲁肽治疗前后血清miRNA-19a表达水平的变化,并分析其与胰岛β细胞功能变化的相关性。方法采用μParaflo~(TM)miRNA微流体芯片技术检测并筛选出血清中表达丰度有变化的miR-19a,分别测定使用利拉鲁肽治疗前后HbA_1C、血清miR-19a表达和胰岛功能水平。结果芯片检测发现,差异表达最明显的miRNA有12个,选取miR-19a进行PCR验证。利拉鲁肽治疗12周后,血清中miR-19a表达量和HbA_1c分别为(0.04±0.03)%、(6.13±0.57)%,较治疗前降低;胰岛素0~30 min曲线下面积(AUC_(Ins 0~30))与血糖AUC(AUC_(g 0~30))比值(INSR30),AUC_(Ins 0~120)/AUC_(g 0~120)比值(INSR120)及Matsuda胰岛素、敏感指数分别为(1.93±0.63)、(3.94±2.27)及(7.86±3.81),较治疗前增加(P0.05)。结论利拉鲁肽治疗新诊断T2DM,胰岛β细胞功能的改善可能与血清中miR-19a表达下调有关。
[Abstract]:Objective to investigate the differential expression of serum microRNA (miRNA) expression profiles in newly diagnosed T2DM patients and healthy people. Analysis of the expression of miRNA-19a in serum before and after liraglutide treatment, and to analyze its correlation with pancreatic beta cell function change. Using the method of Paraflo~ (TM) expression abundance changes of miR-19a miRNA microfluidic chip technology in the detection and screening of blood serum, the use of liraglutide treatment before and after HbA_1C, the expression of miR-19a in serum and pancreatic islet function levels were measured. Results the chip detection showed that there were 12 most distinct expressions of miRNA, and miR-19a was selected for PCR verification. Liraglutide 12 weeks after the treatment, the expression of miR-19a and HbA_1c respectively in serum (0.04 + 0.03)% and (6.13 + 0.57)%, lower than before treatment; insulin area under the curve of min (0~30 AUC_ (Ins 0~30) AUC (AUC_) and blood glucose (g 0~30)) ratio (INSR30), AUC_ (Ins 0~120) /AUC_ (g 0~120) ratio (INSR120) and insulin sensitivity index Matsuda, respectively (1.93 + 0.63), (3.94 + 2.27) and (7.86 + 3.81), higher than those before treatment (P0.05). Conclusion liraglutide treatment of newly diagnosed T2DM, beta cell function improvement may be associated with the down-regulation of miR-19a in serum.
【作者单位】：东南大学医学院附属江阴医院内分泌科;
【基金】：国家自然科学基金(81370920) 江阴市卫生局重点项目(Z201401)资助
【分类号】：R587.1
【正文快照】： 胰岛P细胞功能减退是T2DM主要病理生理基础之一。相关研究[1]表明,micr0RNA(miRNA)通过调控膜岛素分泌、发育及胰岛(3细胞分化维持葡萄糖动态平衡。现有的降糖药物中,利拉鲁肽作为胰升糖素样肽-KGLP-1)类似物,以葡萄糖浓度依赖性作用于胰岛(3细胞,促进胰岛素基因的转录与表达

【相似文献】